Comparative Pharmacology
Head-to-head clinical analysis: DEXTROSE 60 versus DEXTROSE 70 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEXTROSE 60 versus DEXTROSE 70 IN PLASTIC CONTAINER.
DEXTROSE 60% vs DEXTROSE 70% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dextrose is a monosaccharide that provides a source of calories and hydration. It increases blood glucose levels and is metabolized to carbon dioxide and water, yielding energy.
Dextrose is a monosaccharide that provides a source of calories and fluid for intravenous administration. It increases blood glucose concentration and is metabolized to carbon dioxide and water, yielding energy.
Intravenous: For hypoglycemia, 0.5-1 g/kg (10-25 g) as 50% solution; for hyperkalemia, 25 g dextrose with 10 units regular insulin IV. For parenteral nutrition, variable per metabolic needs. Infusion rate not to exceed 0.5 g/kg/h.
Adults: Intravenous infusion, dose dependent on clinical need; typically 500 mL of 70% dextrose (350 g) administered as part of parenteral nutrition at a rate not exceeding 0.5 g/kg/h.
None Documented
None Documented
5–10 minutes (for glucose itself; dextrose is glucose). Clinically, rapid distribution and metabolism.
30-60 minutes; clinically relevant in hyperglycemic states or renal impairment where glucose clearance is prolonged
Renal: 100% (unchanged) if renal threshold not exceeded; otherwise, glucosuria. Biliary/fecal: negligible.
100% renal; metabolized to CO2 and water; none excreted unchanged under normal conditions
Category C
Category C
Intravenous Hypertonic Dextrose Solution
Intravenous Hypertonic Dextrose Solution